Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study
Purpose: This cohort study evaluates therapeutic efficacy and adverse events (AEs) of various overactive bladder (OAB) medications for patients with central nervous system (CNS) disorders. Methods: Patients with OAB and CNS disorders were prospectively enrolled. They were randomly allocated to 3 dif...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Journal of the Formosan Medical Association |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664622001474 |
| _version_ | 1798000939799412736 |
|---|---|
| author | Sheng-Fu Chen Yao-Chi Chuang Chung-Cheng Wang Chun-Hou Liao Hann-Chorng Kuo |
| author_facet | Sheng-Fu Chen Yao-Chi Chuang Chung-Cheng Wang Chun-Hou Liao Hann-Chorng Kuo |
| author_sort | Sheng-Fu Chen |
| collection | DOAJ |
| description | Purpose: This cohort study evaluates therapeutic efficacy and adverse events (AEs) of various overactive bladder (OAB) medications for patients with central nervous system (CNS) disorders. Methods: Patients with OAB and CNS disorders were prospectively enrolled. They were randomly allocated to 3 different treatment subgroups: (1) mirabegron 50 mg once daily (2) solifenacin 5 mg per day, and (3) combined solifenacin 5 mg and mirabegron 50 mg once daily. Efficacy and safety questionnaires and objective parameters were compared among the subgroups, and subgroups between baseline and 3 and 6 months after treatment. AEs, including cognitive dysfunction, were assessed using the Mini-Mental State Examination (MMSE). Results: 102 patients (mean age, 71.8 ± 8.7 years) were enrolled, including 35, 36, and 31 patients received mirabegron monotherapy, solifenacin monotherapy, and combination therapy, respectively. OAB symptoms scores all significantly improved 3 months after treatment in different subgroup. However, PVR increased and VE decreased significantly after treatment in patients receiving solifenacin monotherapy and combination therapy. Dry mouth and constipation were the most common AEs, especially in the solifenacin and combination subgroups. Mild incidence of AEs was noted in patients receiving mirabegron monotherapy. No significant change in MMSE was noted among the subgroups after treatment. Conclusion: OAB medication had good therapeutic efficacy in patients who had OAB with CNS disorders, especially in cerebrovascular accident and parkinsonism. No OAB medication or their combination affected cognitive function, whereas minimal AEs were noted with mirabegron. Mirabegron could be recommended as the first choice for managing OAB in these patients. |
| first_indexed | 2024-04-11T11:28:13Z |
| format | Article |
| id | doaj.art-70ac58de1ddd43a8b7c7fccd9bc90f2b |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-04-11T11:28:13Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-70ac58de1ddd43a8b7c7fccd9bc90f2b2022-12-22T04:26:14ZengElsevierJournal of the Formosan Medical Association0929-66462022-10-011211021012108Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort studySheng-Fu Chen0Yao-Chi Chuang1Chung-Cheng Wang2Chun-Hou Liao3Hann-Chorng Kuo4Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, TaiwanDepartment of Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TaiwanDepartment of Urology, En Chu Kong Hospital, New Taipei City 23702, TaiwanSchool of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Division of Urology, Department of Surgery, Cardinal Tien Hospital, New Taipei City, TaiwanDepartment of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan; Corresponding author. Department of Urology, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung Yang Road, Hualien, Taiwan. Fax: +886 3 8560794.Purpose: This cohort study evaluates therapeutic efficacy and adverse events (AEs) of various overactive bladder (OAB) medications for patients with central nervous system (CNS) disorders. Methods: Patients with OAB and CNS disorders were prospectively enrolled. They were randomly allocated to 3 different treatment subgroups: (1) mirabegron 50 mg once daily (2) solifenacin 5 mg per day, and (3) combined solifenacin 5 mg and mirabegron 50 mg once daily. Efficacy and safety questionnaires and objective parameters were compared among the subgroups, and subgroups between baseline and 3 and 6 months after treatment. AEs, including cognitive dysfunction, were assessed using the Mini-Mental State Examination (MMSE). Results: 102 patients (mean age, 71.8 ± 8.7 years) were enrolled, including 35, 36, and 31 patients received mirabegron monotherapy, solifenacin monotherapy, and combination therapy, respectively. OAB symptoms scores all significantly improved 3 months after treatment in different subgroup. However, PVR increased and VE decreased significantly after treatment in patients receiving solifenacin monotherapy and combination therapy. Dry mouth and constipation were the most common AEs, especially in the solifenacin and combination subgroups. Mild incidence of AEs was noted in patients receiving mirabegron monotherapy. No significant change in MMSE was noted among the subgroups after treatment. Conclusion: OAB medication had good therapeutic efficacy in patients who had OAB with CNS disorders, especially in cerebrovascular accident and parkinsonism. No OAB medication or their combination affected cognitive function, whereas minimal AEs were noted with mirabegron. Mirabegron could be recommended as the first choice for managing OAB in these patients.http://www.sciencedirect.com/science/article/pii/S0929664622001474Central nervous systemCognitive impairmentOveractive bladderMirabegronAntimuscarinics |
| spellingShingle | Sheng-Fu Chen Yao-Chi Chuang Chung-Cheng Wang Chun-Hou Liao Hann-Chorng Kuo Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study Journal of the Formosan Medical Association Central nervous system Cognitive impairment Overactive bladder Mirabegron Antimuscarinics |
| title | Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study |
| title_full | Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study |
| title_fullStr | Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study |
| title_full_unstemmed | Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study |
| title_short | Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study |
| title_sort | therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system disorders a cohort study |
| topic | Central nervous system Cognitive impairment Overactive bladder Mirabegron Antimuscarinics |
| url | http://www.sciencedirect.com/science/article/pii/S0929664622001474 |
| work_keys_str_mv | AT shengfuchen therapeuticefficacyandcognitiveadverseeventsofoveractivebladdermedicationinpatientswithcentralnervoussystemdisordersacohortstudy AT yaochichuang therapeuticefficacyandcognitiveadverseeventsofoveractivebladdermedicationinpatientswithcentralnervoussystemdisordersacohortstudy AT chungchengwang therapeuticefficacyandcognitiveadverseeventsofoveractivebladdermedicationinpatientswithcentralnervoussystemdisordersacohortstudy AT chunhouliao therapeuticefficacyandcognitiveadverseeventsofoveractivebladdermedicationinpatientswithcentralnervoussystemdisordersacohortstudy AT hannchorngkuo therapeuticefficacyandcognitiveadverseeventsofoveractivebladdermedicationinpatientswithcentralnervoussystemdisordersacohortstudy |